Tumor models established using IFNAR1-deficient tumor cells (i.e., MC38 colorectal carcinoma, B16F10 melanoma, and KPC pancreatic cancer cells) exhibited improved therapeutic responses to IR in a CD8+ T cell-mediated manner [104]. This evidence concerns the gene CD8A and pancreatic neoplasm.